Table 1 Patient enrollment by dose level... | American Society of Hematology

Table 1

Patient enrollment by dose level and phase of study

Schedule	dose, mg/m²	Phase 1, n	Phase 2, n	Total, N
QW	0.7*	3*	—	9*
	1.0*	3*	—
	1.3*	3*	—
	1.6	6†	12	18
BIW	0.7*	3*	—	9*
	1.0*	6*	—
	1.3	7‡	27	34
Total		31	39	70

Schedule	dose, mg/m²	Phase 1, n	Phase 2, n	Total, N
QW	0.7*	3*	—	9*
	1.0*	3*	—
	1.3*	3*	—
	1.6	6†	12	18
BIW	0.7*	3*	—	9*
	1.0*	6*	—
	1.3	7‡	27	34
Total		31	39	70

BIW indicates twice-weekly schedule; QW, once-weekly schedule; and —, not applicable.

Patients treated at doses lower than the recommended (maximum planned) doses on each schedule, which were evaluated in the phase 2 portion of the trial.

†

One patient experienced a dose-limiting toxicity of grade 3 restrictive cardiomyopathy.

‡

One patient experienced a dose-limiting toxicity of grade 3 congestive cardiac failure.

View Large

This Feature Is Available To Subscribers Only